Eli Lilly plans to invest $850 million in its U.S. operations in 2017, the company said Friday.
Lilly said its investments span facilities across its U.S. enterprise, including research laboratories, manufacturing sites, and general and administrative areas, driven by demand for Lilly products, as well as its robust pipeline of potential medicines in development targeting cancer, pain, diabetes and other unmet medical needs.
Company leaders were joined by federal, state and local government officials at Lilly Technology Center, where the details of the investments were unveiled, including plans for a new $85 million expansion of its Trulicity (dulaglutide) device assembly operations in the U.S.
This expansion is part of a five-year Lilly’s investment to expand its diabetes manufacturing operations in the U.S., which also includes a $140 million insulin cartridge production facility that was officially dedicated at today’s announcement, Lilly said.
David A. Ricks, Lilly’s president and chief executive officer, said that Lilly’s potential for growth and its long-standing commitment to the U.S. market led to its decision to invest in its U.S. operations and expand its manufacturing footprint in Indianapolis.
“Our future at Lilly is bright, as we’re on a path to launch 20 new products in a 10-year time frame,” Ricks said. “As we have for our entire 140-year history, we continue to see Indiana and the United States as attractive places to research and make the medicines that we sell around the world.”
Ricks explained that Lilly’s $850 million investment will fund both projects that are already underway as well as new projects that will be initiated throughout the course of the year, including additional projects in Indianapolis.